Back to Search
Start Over
Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction program.
- Source :
-
Journal of clinical lipidology [J Clin Lipidol] 2020 May - Jun; Vol. 14 (3), pp. 352-360.e6. Date of Electronic Publication: 2020 Apr 08. - Publication Year :
- 2020
-
Abstract
- Background: Patients with familial hypercholesterolemia (FH) are prone to develop acute myocardial infarction (AMI) at a younger age.<br />Objectives: The aim of the present study was to assess 5-year outcomes after AMI according to the presence of FH in a large multicenter cohort of patients.<br />Methods: The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction consists of nationwide surveys recruiting patients over a 1- to 2-month period every 5 years. Patients recruited in 2005 and 2010 were followed up to 5 years.<br />Results: Of 5147 patients discharged alive and in whom FH status could be assessed, 2.8% had probable/definite FH, using an adapted Dutch Lipid Clinic score. They were 12 years younger, on average, than non-FH patients. Before adjustment, their 5-year survival and event-free survival did not differ from non-FH patients. After adjustment, however, both mortality (hazard ratio [HR] 1.82, 95% confidence interval [CI] 1.15-2.89; P = .011) and the combined endpoint of death, AMI, or stroke (HR 2.22, 95% CI: 1.51-3.26; P < .001) were higher in FH patients. The higher risk in FH patients was also present in patients receiving high-intensity lipid-lowering therapy at discharge: adjusted HR for mortality 2.29, 95% CI: 1.18 to 4.47, P = .015; HR for cardiovascular events 2.57, 95% CI: 1.48 to 4.48, P = .001. Concordant results were observed in propensity score-marched cohorts.<br />Conclusions: The risk of long-term mortality and cardiovascular events is twice as high in FH than in non-FH patients, when adjusted on baseline characteristics, even for those receiving high-intensity lipid-lowering therapy. Additional therapeutic measures are needed in these patients.<br /> (Copyright © 2020. Published by Elsevier Inc.)
- Subjects :
- Aged
Cohort Studies
Female
France epidemiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Hyperlipoproteinemia Type II drug therapy
Hyperlipoproteinemia Type II epidemiology
Male
Middle Aged
Prognosis
Risk Factors
Surveys and Questionnaires
Hyperlipoproteinemia Type II complications
Hyperlipoproteinemia Type II diagnosis
Non-ST Elevated Myocardial Infarction complications
Registries
ST Elevation Myocardial Infarction complications
Subjects
Details
- Language :
- English
- ISSN :
- 1933-2874
- Volume :
- 14
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of clinical lipidology
- Publication Type :
- Academic Journal
- Accession number :
- 32527469
- Full Text :
- https://doi.org/10.1016/j.jacl.2020.03.008